The purine analogs fludarabine (FAMP), 2-chlorodeoxyadenosine (2-CDA) and 2-deoxycoformycin (DCF) comprise a novel group of agents with high activity in low-grade lymphoid malignancies. Although all three agents share several mechanisms of action, such as the induction of apoptosis, and toxic effects, such as prolonged immunosuppression, their activity appears to be different in different disorders. While FAMP and possibly also 2-CDA are highly active in chronic lymphocytic leukemia and low-grade follicular lymphomas, 2-CDA and DCF are most effective in hairy cell leukemia. However, prospective comparative evaluations are in progress and their results may ultimately help to define the appropriate indications for and potential side effects of these highly promising new agents.
Introduction
Low-grade non-Hodgkin's lymphomas (NHL) and chronic lymphocytic leukemia (CLL) comprise a heterogeneous group of disorders which are characterized by a low-proliferative activity and a slowly-to intermediately-progressive clinical course with a median survival time of 3 to more than 10 years. Except for allogeneic and possibly autologous bone marrow or peripheral blood stem cell transplantation, no curative therapy is currently available for either low-grade NHL or CLL. Hence, therapeutic management is directed towards palliation and cytostatic therapy is usually withheld until the appearance of disease-associated symptoms. Frequently used regimens consist of chlorambucil with or without prednisone or cyclophosphamide, vincristine and prednisone (COP) which may be complemented by anthracyclines, especially in highrisk subgroups of CLL. Although these regimens induce partial or even complete remissions in the majority of patients, they reveal no curative potential and most patients ultimately die of progressive disease [1, 2] . Hence, new and more effective agents are sorely needed to improve the therapeutic prospects of patients with low-grade NHL and CLL. The development of the structurally related purine analogs, fludarabine phosphate, 2-deoxycoformycin and 2-chlorodeoxyadenosine, and their introduction into the treatment of low-grade lymphoid malignancies has not only enlarged the armentarium of active drugs but may also provide the basis for development of more effective and even curative treatment strategies.
Fludarabine monophosphate (FAMP)
Fludarabine monophosphate (FAMP) emerged from the search for more effective derivatives of cytosine arabinoside which is one of the most active single agents in the treatment of acute leukemias and highgrade lymphomas. One of the first analogs to be synthesized was 9-[}-D-arabinofuranosyladenine (vidarabine). This compound was found to be rapidly inactivated in vivo by the enzyme adenosine deaminase, which limited its anticancer activity. Attempts to develop a water-soluble and adenosine deaminase-resistant drug led to the formulation of 9-p-D-arabinofuranosyl-2-fluoroadenine-5'-monophosphate (2-fluoro-AMP = fludarabine-monophoFphate) ( construct the halogenated purine ring protects the molecule against deamination by adenosine deaminase while the addition of the monophosphate moiety renders the drug water soluble and highly bioavailable [5, 6] .
Clinical pharmacology and mechanisms of action
After intravenous injection FAMP is rapidly dephosphorylated to F-ara-A which is taken up into the cell by an energy-dependent transmembrane carrier system [7] [8] [9] . Intracellularly F-ara-A is phosphorylated to its triphosphate F-ara-ATP through the action of the deoxycytidine kinase system. F-ara-ATP is incorporated into the DNA and acts as a DNA chain-terminator. It also inhibits the synthesis and repair of a number of key enzymes of DNA, including DNA polymerase alpha, DNA primase and DNA ligase [10] [11] [12] . Its action is potentiated by the decrease of cellular dATP pools resulting from inhibition of ribonucleotide reductase by F-ara-AMP. The incorporation of F-ara-AMP into mRNA results in the premature termination of RNA transcription and impairs its function as a template for protein synthesis [10] . These mechanisms reflect the action of fludarabine in dividing cells but do not explain its activity against cells with a low proliferative activity in which the induction of programmed cell death (apoptosis) appears to comprise the major cytotoxic event [13] . Preliminary data indicate differences in fludarabine metabolism between malignant lymphocytes and normal hematopoetic progenitor cells. F-ara-ATP elimination is substantially slower in lymphoblasts than in normal bone marrow cells, resulting in higher intracellular F-ara-ATP levels and a potential therapeutic selectivity [14, 15] . Through its action on intracellular enzymes, and on ribonucleotide reductase in particular, FAMP also potentiates the formation of ara-CTP after administration of ara-C in leukemic blasts [16] and CLL lymphocytes [17] , providing new perspectives for fludarabine based combination regimens in these disorders.
Fludarabine plasma kinetics follow a triphasic function with a terminal half-life of F-ara-A of 30 hours [7, 8, 15] . The long half-life of fludarabine provided the rationale for using a daily i.v. bolus of 25-30 mg for 5 days repeated at 4-week intervals, which represents the currently accepted schedule [8, 15, 18, 19] . Fludarabine has an oral bioavailability of 75% when administered in liquid form [20] and appears to be well-qualified for oral application in the near future.
Treatment results
The activity of fludarabine is mainly restricted to hematologic disorders and in particular to low-grade lymphoid malignancies. In spite of promising results in preclinical evaluations [21] fludarabine appears to be inactive in the treatment of various solid tumors [23] [24] [25] .
Chronic lymphocytic leukemias (CLL)
In CLL fludarabine has been evaluated in several noncomparative phase I and II studies which revealed a high activity in relapsed or refractory disease [3, [30] [31] [32] [33] [34] [35] [36] [46] [47] [48] (Table 1) . Grever et al. [31] , the first who administered fludarabine to patients with relapsed progressive CLL, noted responses in 4 of 32 evaluable patients and clinical improvement in an additional 15 cases. Keating and coworkers [32] treated 68 patients with relapsed and refractory CLL and observed 13% complete (CR) and 44% partial remissions (PR) as defined by NCI criteria Survival was correlated with the Rai stage achieved, with only marginal differences in patients with a nodular CR (nCR) characterized by residua] bone marrow nodules only, and the group of complete responders experiencing a median survival of The results of a comparatively long-term analysis were recently published by Keating et al. [4] , who followed the clinical course of 113 patients with CLL for a median of three years after fludarabine monotherapy. They showed a strong association between response and survival and the number of prior treatments, responsiveness to alkylating agents and the Rai or Binet stages.
Fludarabine was also used in combination with other agents. Based on the activity of both substances in CLL, Robertson et al. [39] treated 29 CLL patients with fludarabine and doxorubicin achieving 4% complete remissions, 13% nodular CR and 42% partial remissions (Table 4 ). In a comparative trial O'Brien et al. [3] investigated 264 patients with CLL, 95 untreated and 169 pretreated, who received either fludarabine monotherapy or a combination with prednisone (Table  4) . Additional corticosteroids did not influence the overall response or survival. However, a higher incidence of opportunistic infections, in particular by Listeria monocytogenes and Pneumocystis carinii pneumonia, was encountered in patients receiving additional prednisone. Elias et al. [40] treated 21 patients with fludarabine and chlorambucil without a substantial improvement of activity ( Table 4) .
The combination of fludarabine with ara-C and cisplatin was administered to 17 relapsed fludarabineresistant CLL patients by Robertson and colleagues [42] (Table 4 ). This combination was based on the observation that fludarabine and ara-C act synergistically on the inhibition of DNA repair and induction of DNA damage. Furthermore, additional effects of fludarabine on cisplatin-induced DNA fragmentation have been described. Thirty-five percent of patients treated in this study responded, including 2 with complete remissions. Myelosuppression was common and 71% of patients required hospitalization for infection or renal dysfunction.
The high antileukemic activity of fludarabine in CLL provides a new perspective in the treatment of this disorder, but a final judgment requires a prospective comparison of fludarabine with established regimens. Several trials are currently in progress. In a recent European multicenter trial fludarabine was compared with a combination of cyclophosphamide, doxorubicin and prednisone (CAP) [37] . Pretreated as well as untreated patients were included in both treatment groups. A preliminary analysis disclosed a significantly higher efficacy of fludarabine in both patient groups. The response rates were 70% for fludarabine vs. 58% for CAP in untreated patients and 58% vs. 42% in pretreated patients. Significant differences were also found in treatment-associated side effects, with a higher frequency and degree of nausea and vomiting as well as alopecia after CAP, but a tendency towards more infections after treatment with fludarabine. Similarly, fludarabine appeared more effective than CAP or CHOP in patients with previously untreated stage B disease, as was recently reported by the French Cooperative Group on CLL [38] .
Fludarabine has also been studied in patients with the more aggressive variant of CLL, prolymphocytic leukemia (PLL), which is usually resistant to conventional therapy [43, 44] . Of 13 patients with PLL and 4 with the prolymphocytoid subtype of CLL, 6 responded with a CR to 3 cycles of therapy.
Non-Hodgkin's lymphoma (NHL)
The promising results of fludarabine in CLL prompted its extensive evaluation also in non-Hodgkin's lymphoma (NHL). The majority of patients entering phase II trials had late-stage low-or intermediate-grade disease. As summarized in Table 2 , fludarabine was administered at doses of 18 to 30 mg/m 2 /d i.v. for 5 days every 3 to 4 weeks. An overall response rate of 31%-38% was achieved with CR rates of 4%-18%.
Leiby et al. [51] were the first to show a notable activity of fludarabine in 26 relapsed NHL with a response rate of 32%. The only significant toxicity was myelosuppression which was more severe in patients with bone marrow involvement. Subsequent studies by Redman et al. [52] , Hochster et al. [53] and Whelan and colleagues [54] revealed a favorable outcome, especially for low-grade follicular lymphomas, while small lymphocytic lymphomas, transformed lymphomas, (38) 13 (38) 12 (31) 20 (44) 14 (67) 30 ( mycosis fungoides and Hodgkin's disease were less sensitive (Table 3) . Analysis of the survival of patients responding to fludarabine shows a median of 30.5 months in those with CR [53] . Long-term remissions and prolonged survival are also demonstrated by a phase II study of the German Low-Grade Lymphoma Study Group [55] for the treatment of relapsed or refractory low-grade NHL. Patients achieving response (overall response 39%) experienced a significant improvement of survival, with 50% of the patients being alive 26 months after the start of therapy.
The different mechanisms of action make fludarabine an attractive partner for combination with other cytostatic agents. Hence, fludarabine enhances the crosslinking of cisplatin in LoVo cell lines and may thus overcome cisplatin resistance [60, 61] . Gregoire et al. [62] demonstrated in a murine model that fludarabine has radiosensitizing effects when used in conjunction with radiation therapy. Cytotoxicity seemed to be dose-and schedule-dependent. Experimental data also revealed a synergistic effect of fludarabine and mitoxantrone through the inhibition of DNA repair and prompted evaluation of this combination in a clinical phase I study by McLaughlin et al. [58] (Table 4 ). The promising initial results were confirmed by the most recent update of this trial, which reported an overall response rate of 95% in 38 patients (M. Keating et al., personal communication 1994) . A lower response rate emerged from a recent study of the German Low-Grade Lymphoma Study Group, with achievement of remission in 39% of heavily-pretreated patients [59] (Table 4 ).
Waldenstrom's disease and multiple myeloma
Fludarabine was also administered to patients with Waldenstrom's disease, and remission rates of 36%-45% were obtained (Table 5 ). Response to fludarabine (18) 95 (60) 30 (32) 32 (34) 19 (20) 81 (85) 12 (7) 26 (15) 14 (8) 52 (31) (95) 11 (48) 13 (56) 8 (47) 9 (53) 3 (20) 4 (27) was slow in view of the reduction of the paraprotein gradient, and complete remissions were achieved in only a few cases. In the largest patient population analyzed by Dimopoulos et al. [65] the median overall survival was 31 months, with 12 months for fludarabine-resistant cases (Table 5) . A lambda light-chain paraprotein appeared to be associated with a poorer outcome. Based on the limited available data, fludarabine appears to be inactive in patients with multiple myeloma [63, 64] .
Side effects
In initial phase I and II studies daily doses of > 100 mg/ m 2 fludarabine were applied for the treatment of acute leukemias and solid tumors, and caused devastating central nervous system (CNS) toxicity with progressive encephalopathy in up to 30% of cases. At currently used doses of 25-30 mg/m 2 /d, neurologic side effects are infrequent and consist mainly of somnolence [18] and fatigue [19] . Other side effects include nausea, vomiting and pulmonary toxicity, while hair loss is not observed. Tosti et al. [26] , Bastion et al. [27] and other authors [28, 29] have reported an increased incidence of autoimmune complications. Three patients with CLL experienced severe autoimmune hemolytic anemia after several courses of fludarabine which paralleled the substantial reduction of the malignant B-lymphocytes. A similar increase in autoimmune phenomena was also observed in the course of the above-mentioned comparative trial of fludarabine versus CAP [37] .
The major dose-dependent toxicity is hematologic, and comprises neutropenia, thrombopenia and especially lymphopenia, whereby T-cell subsets are mainly affected [22] . Of special concern is the decrease of CD4+ T-cell counts which appears to be long-lasting and possibly associated with an increased risk of opportunistic infections [3, 30] . However, in a recent analysis of 264 patients with CLL, O'Brien et al. [3] reported no substantial increase in the rate of nosocomial infections after fludarabine treatment except for patients who also received prednisone. Hence, further data from prospective comparative trials are needed to assess the clinical relevance of fludarabine-induced immunosuppression.
2-Deoxycoformycin (DCF)
Clinical pharmacology and mechanisms of action 2-Deoxycoformycin (DCF) is a purine analog harvested from fermentation cultures of the soil organism, Streptomyces antibioticus. It is a potent inhibitor of adenosine deaminase (ADA), a key enzyme in the cellular purine salvage pathway. It binds to ADA due to its resemblance to the transition-state form of adenosine as it is catabolized to inosine [68] . ADA is found in all mammalian tissues, with the highest concentration in lymphoid cells and particularly in T-cells. Correspondingly, a higher cytotoxicity against T-lymphocytes than against B-lymphocytes was revealed for DCF and 2-chlorodeoxyadenosine (2-CDA) in cell line investigations [69] [70] [71] .
After intravenous injection DCF is rapidly distributed throughout the body with a plasma half-life of 11 min. DCF is renally excreted and its terminal half-life is 5.7 h [78] . The inhibition of ADA results in an accumulation of 2-deoxyadenosine and its nucleotides. 2-Deoxyadenosine is phosphorylated by deoxycytidine kinase to dATP, which accumulates in the cells and leads to down-regulation of ribonucleotide reductase [72] . Consecutively, the intracellular pool of deoxynucleotides is depleted and DNA replication and repair are affected. In resting cells where ribonucleotide reductase is inactive, mechanisms of cell death must be different and may comprise the inhibition of DNA repair and the induction of DNA strand breaks and apoptosis [73] [74] [75] 13) .
Treatment results

Hairy cell leukemia
Following the initial report by Spiers et al. [77] about the successful treatment with DCF of 2 patients with hairy cell leukemia, the drug has been intensively investigated in this disorder. Spiers et al. themselves treated a further 37 patients and reported 59% CR and 37% PR rates (overall response rate 96%) (Table 6 ) [78, 79] . Other investigators confirmed these results using different doses and schedules. Reported CR rates range from 33%-89% and total responses from 79%-100% (Table 6 ). Response to DCF seems independent of prior splenectomy and even patients with resistance to interferon-alpha showed clinical improvement [80] [81] [82] [83] [84] . DCF-induced remissions are usually obtained during the first 3-5 months of treatment and appear to be long-lasting, ranging from 12.6 [81] to 14 months [84] . A recent update of the study by Kraut et al. [86] (Table  6) showed that the 16 patients who achieved complete remission remained alive and well for a median of 71.6 months (range 62-89) after initiation of treatment. Seven patients remained in complete remission for a median of 57.8 months (range 52-67). Two of nine relapsed patients required retreatment and again achieved complete remissions [86] .
Most of the patients experienced rapid improvement of peripheral blood cell counts, with platelets first recovering, followed by neutrophils and erythrocytes [84] . In a recent intergroup study conducted by SWOG (Southwest Oncology Group), ECOG (Eastern Cooperative Oncology Group), CALGB (Cancer and Leukemia Group B), and NCIC (National Cancer Institute of Canada Clinical Trials Group), DCF was randomly compared with interferon-alpha 2a in 356 previously untreated patients [85] (Table 6) . A significantly higher rate of complete remissions was obtained by DCF than (87) 25 (89) 16 (59) 37 (56) 11 (33) 31 (82) 103 (69) 29 (37) 26 (76) (23) 15 (46) 6 (16) 9(6) 20 (26) 6 (18) 15 (100) 4 (15) 6 (21) 9 (23) 7 (27) 7 (10) 5 (20) Total 42 (84) 21 (91) 28 (100) 26 (96) 52 (79) 26 (79) 37 (98) 112(75) 49 (63) 32 (94) 15 (100) 5 (19) 7(24) 10 (26) 7 (27) 12 (17) 5 ( by interferon-alpha 2a (69% vs. 11%). Similarly, overall response was higher in the DCF group, with 112/150 (75%) responses as compared to 58/152 (38%) patients responding to interferon. In the group of CR patients, relapse-free survival was significantly longer for DCFtreated patients, of whom 4/103 (4%) relapsed during a period of 13-37 months as compared to the 16 patients achieving CR after interferon-alpha, 8 (50%) of whom relapsed within 10-19 months. The sequential application of DCF and interferon-alpha was assessed by Habermann and his group [89] (Table 6 ) on the promise that this sequence might reduce the risk of DCF-related infections [84] . Although in this series of 34 patients only 4 episodes of severe infections were encountered, the DCF-induced impairment of cellular immune defense [91] [92] [93] constitutes a major concern. Despite a substantial proportion of patients with long-lasting unmaintained remissions, DCF therapy appears to have no curative potential. Hence, Thaler et al. [94] evaluated the long-term effects of DCF in patients with HCL by immunohistochemical and molecular methods, detecting residual hairy cells in the bone marrow of all of those with clinical and cytologic complete remissions.
Chronic lymphocytic leukemias (CLL)
Experience with DCF in the treatment of CLL is limited but suggests a certain activity in relapsed or refractory disease [103] . The accumulated data summarized in Table 6 , however, indicate that DCF is less effective than fludarabine or 2-CDA. Preliminary evidence suggests that DCF may be more beneficial in prolymphocytic leukemia (PLL) [104] . Dohner et al. [105] reported 9 partial remissions (45%) in 20 patients with B-cell PLL (n -14) or T-cell PLL (n -6) after DCF therapy at a dose of 4 mg/m 2 once a week for 3 weeks (Table 6 ). In view of the low response rates of approximately 25% with conventional regimens such as chlorambucil and prednisone, these results appear promising and warrant further exploration.
Non-Hodgkin's lymphoma
Analogous to CLL, experience with DCF in NHL indicates a marginal to moderate activity only. The currently available information from different phase II studies in relapsed and refractory NHL and Hodgkin's disease reveal response rates in the range of 17%-25% only, with remission durations no longer than several weeks to a few months [100] [101] [102] .
DCF therapy may be more advantageous for T-cell lymphomas although the results of only a few patients are thus far available [109] [110] [111] [112] [113] (Table 7) . Grever et al. [110] treated 4 patients with cutaneous T-cell lymphoma (CTCL) and obtained 2 CRs which persisted in unmaintained remission for 5 years, and 2 PRs which lasted for 4 and 9 months. A study with more patients (25) 4 (27) 5 (21) 3 (15) 6 (100) Total 6 (19) 12 (46) 2 (40) 17 (41) 4 (50) 4 (100) 6 (33) 1 (100) 1 (25) 7 (47) 9 (41) 6 (30) (Table 7) . By combining interferon-alpha 2a and DCF, Foss et al. [113] achieved an overall response rate of 41%, and a median progression-free survival of responders of 13.1 months.
In multiple myeloma and refractory or relapsed Waldenstrom's disease DCF has only minor activity [106] [107] [108] .
Side effects
In initial clinical studies in patients with acute leukemias, DCF was administered in high doses of 0.25 to 1.0 mg/kg which were associated with severe toxic effects, including liver and kidney failure, CNS toxicity, conjunctivitis, myalgia and rash [76] . Lower doses are well tolerated and side effects consist predominantly of transient myelosuppression and lymphopenia as well as of mild to moderate nausea and vomiting [96] .
A major concern with respect to DCF treatment is the prolonged reduction of CD4+ and CD8+ lymphocyte subsets causing impaired immune function and infection defense [69, 70, [91] [92] [93] [94] [95] . However, there is no clear correlation between low CD4+ counts and the occurrence of opportunistic infections [80, [91] [92] [93] 114] . Considering that hairy cell leukemia itself is characterized by pancytopenia and a profound monocytopenia as well as an increased risk of infection [111] , the side effects of DCF on the immune system need to be evaluated in comparative prospective studies.
2-Chlorodeoxyadenosine (2-CDA)
Clinical pharmacology and mechanisms of action
Substitution of chloride for hydrogen at the 2' position of the purine ring of 2'-deoxyadenosine renders 2-chlorodeoxyadenosine (2-CDA) resistant to deamination. 2-CDA is phosphorylated by the deoxycytidine kinase system to its 5'-triphosphate, the putative active form. The excess of 2-CDA 5'-triphosphate inhibits ribonucleotid reductase and consequently DNA synthesis in replicating cells [72] . Lymphocytes have a high level of deoxycytidine kinase, which may account for their high sensitivity to 2-CDA. As has been proposed for the effects of fludarabine and 2-deoxycoformycin, cytotoxicity in non-replicating cells seems to be the result of a combination of events including the inhibition of DNA repair [73] , the induction of lethal DNA damage [74] and apoptosis [13] .
2-CDA is cleared rapidly after i.v. injection, with an initial half-life of 36 min followed by a slower second phase with a half-life of 7 h. Different methods of administration have been used including 24-h continuous, and intermittent 2-h infusions for 7 consecutive days [121] . 2-CDA has an oral bioavailability of 50% and may thus also be applicable via the oral route [122, 123] .
Treatment results
Hairy cell leukemia
For the first time, in 1987 2 patients with hairy cell leukemia were treated by Piro et al. [125] with a single infusion of 2-CDA (0.1 mg/kg/d for 7 days) and both experienced long-lasting complete remissions. These favorable results were replicated in 148 subsequent HCL patients, 97% of whom responded with 85% complete and 12% partial remissions [126] . Responses were independent of previous splenectomy or prior interferon therapy and were remarkably long-lasting, with only four relapses after a median observation time of 36 months [127] . Favourable results were also reported in most of the other series summarized in Table 8 .
As demonstrated by Saven and Piro in 1993 [129] , 2-CDA is not cross-resistant with DCF. Of 5 patients who were resistant to or unable to tolerate DCF therapy, 4, including 2 with primary resistance to DCF, responded to 2-CDA with complete remissions. At a median observation time of 10 months (range 2 to 14 months) 3 patients are still in unmaintained remission.
In spite of these promising results 2-CDA is not able to eradicate the malignant clone completely. Filleule et al. [130] recently disclosed their demonstration of residual disease by molecular genetic methods in all analyzed patients, some of whom were in long-lasting complete remission. [132] Sorensen et al. [137] No of. (85) 16 (80) 6 (75) 9 (82) 36 (78) 12 (75) 50 ( (97) 20 (100) 8 (100) 11 (100) 41 (89) 12 (75) 86 (79) 2-CDA was administered for 7 days as a continuous infusion.
2-CDA-associated side effects predominantly comprise myelosuppression and a decrease of CD4+ lymphocytes which may persist for a long period of time [133] . Correspondingly, a higher incidence of opportunistic infections and fever of unknown origin has been reported by several investigators [131, 132] . However, the frequency of late-occurring infections did not increase and in some patients even an improvement of CD4+/CD8+ counts was observed after 2-CDA treatment [133] . Hence, a final judgment of 2-CDA therapyassociated toxicity must wait upon the results of ongoing prospective randomized trials.
Non-Hodgkin's lymphoma and chronic lymphocytic leukemia Piro et al. [138] were the first to investigate 2-CDA in 18 patients with CLL who had relapsed or were refractory to prior alkylating agents and prednisone (Table  9 ). Only 4 patients showed partial responses, and another 6 had clinical improvement of their disease. Three of four patients with autoimmune hemolytic anemia experienced a resolution of hemolysis. From a subsequent series of 86 patients 2 achieved a complete remission and 46 a partial response for an overall response rate of 55% (Table 9) . Comparable results were also reported by other investigators, with remission rates ranging from 44% to 67% (Table 9 ). Juliusson and Liliemark [142] observed that patients relapsing after 2-CDA therapy responded to 2-CDA reexposure, indicating that CLL cells retain their sensitivity to 2-CDA.
Experience with 2-CDA in NHL is still limited. Available data indicate a significant activity in lowgrade follicular NHL, whereas the diffuse subtypes and high-grade NHL are less sensitive [144] . Overall remission rates are in the range of 43% to 54% (Table 9) .
In CLL and NHL myelosuppression was the dose limiting toxicity, occurring in 25% of cycles after administration of 2-CDA at a dose of 0.1 mg/kg/d for 7 days [139, 140, [143] [144] [145] [146] [147] ).
An early report by Juliusson et al. [147] about a high rate of response to 2-CDA in patients who had failed on prior fludarabine therapy elicited great interest. The results, however, were not confirmed by other groups [148, 149] , and in a more recent study by O'Brien et al. [139] only 2 (7%) partial responses were obtained by 2-CDA in a group of 28 CLL patients who had failed prior fludarabine treatment. A further study with 2-CDA in patients with Waldenstrom's disease who had relapsed after prior fludarabine treatment confirms the cross-resistance of both drugs [156] . Hence, crossover retreatment should rather be discouraged to avoid the potential hazards of severe myelo-and immune suppression.
Acute leukemias
The antimetabolite nature of 2-CDA prompted its evaluation also in acute leukemias. Following an initial phase I trial [150] with escalating doses of 2-CDA from 3 to 10.7 mg/m 2 a subsequent phase II study [151] revealed a 47% CR rate in 17 children with relapsed AML. Only one response was obtained in 7 cases of childhood ALL. These results could not be confirmed by Vadath et al. [152] and further studies are needed to elucidate the activity of 2-CDA in acute leukemias.
Side effects
Like fludarabine and DCF, treatment with 2-CDA is immune-suppressive and leads to a decrease in the CD4+/CD8+ ratio for an extensive period of time exceeding 12 to even 24 months [133, [153] [154] [155] . In contrast, 2-CDA seems to normalize an impaired natural killer (NK) cell function, leading to a rapid restoration of NK function within 2 months after therapy [155] . As for the other purine analogs, further data and a longer observation time are needed to judge the potential long-term risks and benefits originating from these findings.
Conclusions and future directions
The introduction of purine analogs into the treatment of lymphoid malignancies made a substantial impact on the management of lymphoid mahgnancies and may render possible the exploration of novel treatment strategies with curative potential which have not been available before now. Hence, high rates of complete hematologic remissions are achieved in CLL by fludarabine and possibly also by 2-CDA which may provide the basis of additional therapeutic approaches such as interferon-alpha maintenance or even myeloablative chemo-radiotherapy followed by autologous bone marrow or peripheral stem cell transplantation. In hairy cell leukemia DCF and 2-CDA induce long-lasting remissions which in spite of persistant residual disease may improve long-term survival and comprise operational cure. Further studies are certainly needed to explore these approaches and also to define the most appropriate differential indications.
For the treatment of hairy-cell leukemia 2-deoxycoformycin and 2-chlorodeoxyadenosine are clearly superior to fludarabine. The capability of achieving high rates of complete responses with only one treatment cycle suggest that 2-CDA may become the standard therapy for HCL. A comparative evaluation of DCF and 2-CDA is needed, however, to evaluate possible differences in remission induction and durability of responses as well as potential long-lasting side effects. Similarly, an important issue in the therapy of NHL and CLL is the comparative role of 2-CDA and fludarabine. Prospective comparative trials are needed which could show fludarabine to be the most active agent. Still, despite these promising prospects, potential side effects should not be overlooked. Hence, the persistant suppression of CD4+ lymphocytes may not only facilitate the emergence of opportunistic infections, but may also enhance the risk of secondary malignancies. In addition, the early introduction of purine analogs into the treatment of indolent disorders such as CLL or low-grade NHL with a long clinical course may induce chemoresistance to other agents, as was recently suggested by the enhanced expression of MDR 1 (multiple drug resistance) in CLL after fludarabine therapy.
These results therefore caution against the use of purine analogs outside clinical trials and encourage participation in ongoing prospective studies which will ultimately help to define the appropriate indications for and timing of these promising new agents.
